High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group.

Current treatments for metastatic breast cancer are not associated with significant survival benefits despite response rates of over 50%. High-dose therapy with autologous bone marrow transplantation (ABMT) has been investigated, particularly in North America, and prolonged survival in up to 25% of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameron, D. A., Craig, J., Gabra, H., Lee, L., MacKay, J., Parker, A. C., Leonard, R. C., Anderson, E., Anderson, T., Chetty, U., Dixon, M., Hawkins, A., Jack, W., Kunkler, I., Leonard, R., Matheson, L., Miller, W.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074804/
https://www.ncbi.nlm.nih.gov/pubmed/8980406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074804/
https://www.ncbi.nlm.nih.gov/pubmed/8980406

Ejemplares similares